Navigation Links
Intarcia Presents Compelling 48-week Results for ITCA 650 - Data Underlines the Promise to Become the First Injection-free GLP-1 Therapy at the 47th Annual EASD Meeting in Lisbon
Date:9/14/2011

mcg/day experienced a statistically significant improvement in their quality of life after 8 weeks of ITCA 650 therapy compared with their level of satisfaction at study entry on oral metformin therapy. Patients on either dose of ITCA 650 also experienced a greater increase in their level of satisfaction with treatment compared with patients on twice-daily self-injections of exenatide.  Results of the week 20 assessment showed a statistically significant improvement in treatment satisfaction among patients switching to ITCA 650 from exenatide injection. The substantial improvement observed among patients initially randomized to ITCA 650 was maintained after transition to higher doses of ITCA 650.

ITCA 650 Pharmacokinetics and PharmacodynamicsIn the same session, Intarcia's Chief Medical Officer, Kenneth L. Luskey, MD, presented an analysis of pharmacokinetics and pharmacodynamics from the ITCA 650 48-week phase 2 study.  Results of the analysis confirmed that treatment with ITCA 650 achieves steady state plasma levels of exenatide within 24-48 hours and provides continuous exposure and consistent plasma levels of exenatide for up to 48 weeks.  Following removal of ITCA 650, exenatide levels became undetectable within 24 hours.  Nearly all patients responded to ITCA 650, and greater reductions in HbA1c, FPG and body weight were observed among patients with the highest plasma exenatide concentrations.

The ITCA 650 phase 3 program, planned for late 2011 initiation, will evaluate treatment regimens involving initial 3-month ITCA 650 dosing at 20 mcg/day transitioning to 60 mcg/day and thereafter using ITCA 650 devices of both 6- and 12-month durations.

A downloadable version of the ITCA 650 presentations from EASD are available on the Intarcia corporate website at: http://www.intarcia.com/media_presentations.html

About ITCA 650ITCA 650 therapy for type 2
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
2. Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals
3. Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD
4. Intarcia Therapeutics Executive Chairman Kurt Graves to Present at 29th Annual JP Morgan Healthcare Conference
5. Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014  Australian drug delivery company, Phosphagenics Limited ... raised A$19.3 million via a placement of A$16.3 million ... the U.S., Asia and ... share purchase plan (SPP) to be offered to existing ... in two tranches. "This capital raising positions ...
(Date:7/11/2014)... York , July 11, 2014 ... Transparency Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic Operative ... Share, Growth, Trends and Forecast, 2013-2019" the global endoscopy ... 2012 and is expected to grow at a CAGR ... estimated value of USD 36.9 billion in 2019. ...
(Date:7/11/2014)... , July 11, 2014  Veran Medical ... announced today the positive, cost-effective final results ... SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous biopsy ... percutaneous approach to biopsy when a traditional ... and physicians experience positive financial outcomes when ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Veran Medical Publishes Lung Cancer Patient Management Study 2
... Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) management ... Tuesday, October 25th at 11:30 a.m. Pacific/ 2:30 p.m. Eastern/ ... the Palace Hotel in San Francisco. The ... for replay after the presentation. The webcast can be accessed ...
... Colo., Oct. 18, 2011 SomaLogic, Inc., announced today ... with Novartis to use its unique proprietary proteomics technology ... "We are excited by this opportunity to ... robust biomarkers, validate novel drug targets, and even develop ...
Cached Medicine Technology:SomaLogic Announces Research Agreement with Leading Global Pharmaceutical Company to Accelerate Pharmaceutical Discovery and Development 2
(Date:7/14/2014)... Rock Hill, SC (PRWEB) July 14, 2014 ... vegetables, but a study by the School of Public ... fruit and vegetable consumption had a near-zero effect on weight ... foods must be combine with some form of portion ... is a method of monitoring portions and controlling how much ...
(Date:7/14/2014)... Sometimes, thinking “inside the box” can be ... first product release, Joyboxx™ - The world’s only hygienic ... , Inventor and CEO, Deborah Semer began designing a ... solution for their ‘toys’ after she realized no such ... , Semer met 30-year industry veteran Phyllis Heppenstall, the ...
(Date:7/14/2014)... EurekaMag.com has newly published results of 64,900 ... disease that ranges in severity from a mild ... illness that attacks the liver. An estimated 3.2 million ... virus infection of which approximately 80% of people develop ... all studies on Hepatitis C , the Life, Earth ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 "Medical devices, ... one of us. The Tri-Valley is a star when ... based in the region are working on amazing products ... the face of medicine," according to Dale Kaye CEO ... To showcase some of the brilliant minds and businesses ...
(Date:7/14/2014)... WI (PRWEB) July 14, 2014 Doctor ... announced the launch of their new company website. The ... valuable free information on chiropractic marketing. It's also a ... that Inception has to offer. , When contacted at ... the newest version of our main website. Our site ...
Breaking Medicine News(10 mins):Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 2Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 3Health News:Passionate Playground launches Joyboxx 2Health News:Passionate Playground launches Joyboxx 3Health News:EurekaMag.com Publishes 64,900 New Studies on Hepatitis C 2Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 2Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 3Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 4Health News:Doctor Mike Hamilton From Inception Chiropractic Websites Announces the Launch of Their New Website 2
... (CDC)’s Morbidity and Mortality Weekly Report, West Virginia has a ... the U.S. Virgin Islands has the lowest. ... data collected through the Behavioral Risk Factor Surveillance System, a ... health departments. ,Levels of coronary heart disease, ...
... including four doctors have been accused of cheating insurance ... involved in giving allergy shots to many// patients without ... ,Patients were also not informed about the risk factors ... for testing procedures were not sent to the lab ...
... Genetic factors play an important role in the ... University School of Medicine in St. Louis.// ... genetic variations can influence smoking behaviors and contribute ... ,Scientists suggest that these smoking-related genes may ...
... to make many plastics found in food storage containers ... according to a recent study by Yale School of ... Taylor, M.D., associate professor in the Department of Obstetrics, ... study shows that BPA changes the expression of key ...
... risk of rash, leading to treatment discontinuation or interruption//, ... research published in the January edition of HIV Medicine. ... once daily were more likely to experience liver complications ... For these reasons, the authors conclude that once-daily nevirapine ...
... consumers not to purchase, or use, Wild Kitty Cat Food ... monitoring activities, FDA collected and analyzed a sample of frozen ... product. Cats and other pets consuming this food may become ... if they handle or ingest this cat food, touch pets ...
Cached Medicine News:Health News:Genes for Nicotine Dependence Identified 2Health News:Genes for Nicotine Dependence Identified 3Health News:Genes for Nicotine Dependence Identified 4Health News:Once-daily Nevirapine Has More Side-effects Than Twice-daily Dose 2Health News:Once-daily Nevirapine Has More Side-effects Than Twice-daily Dose 3Health News:Consumers Warned of Using Cat Food Due to Salmonella Contamination 2
High resolution, multi-frequency, HST version of the UST-987-7.5. Provides even greater image detail, better resolution, and penetration....
... Penetration Steered Linear Peripheral Vascular transducer, with ... MHz. It is our newest vascular ... 4 different settings to optimize imaging of ... color and Doppler sensitivity of this transducer ...
... Super High Density, multi-frequency, linear ... "twist on the UST-5536, this ... it sweeps horizontally as well ... axis so that target lesions ...
... The UST-MC11-8731 is a perfect alternative ... are used to seeing more of a ... of the transducer in the hand., This ... shaped convex intraoperative transducer. The UST-MC11-8731 nestles ...
Medicine Products: